These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35275639)

  • 1. Efficient Identification of Anti-SARS-CoV-2 Compounds Using Chemical Structure- and Biological Activity-Based Modeling.
    Xu T; Xu M; Zhu W; Chen CZ; Zhang Q; Zheng W; Huang R
    J Med Chem; 2022 Mar; 65(6):4590-4599. PubMed ID: 35275639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
    Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
    Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
    Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
    ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
    Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
    Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of SARS-CoV-2 viral entry inhibitors using machine learning and cell-based pseudotyped particle assay.
    Sun H; Wang Y; Chen CZ; Xu M; Guo H; Itkin M; Zheng W; Shen M
    Bioorg Med Chem; 2021 May; 38():116119. PubMed ID: 33831697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen.
    Wang L; Yu Z; Wang S; Guo Z; Sun Q; Lai L
    Eur J Med Chem; 2022 Dec; 244():114803. PubMed ID: 36209629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
    Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
    Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL
    Rawson JMO; Duchon A; Nikolaitchik OA; Pathak VK; Hu WS
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33498923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtual screening of anti-HIV1 compounds against SARS-CoV-2: machine learning modeling, chemoinformatics and molecular dynamics simulation based analysis.
    Nand M; Maiti P; Joshi T; Chandra S; Pande V; Kuniyal JC; Ramakrishnan MA
    Sci Rep; 2020 Nov; 10(1):20397. PubMed ID: 33230180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of naturally occurring inhibitors against SARS-CoV-2 3CL
    Xiong Y; Zhu GH; Wang HN; Hu Q; Chen LL; Guan XQ; Li HL; Chen HZ; Tang H; Ge GB
    Fitoterapia; 2021 Jul; 152():104909. PubMed ID: 33894315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
    Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19.
    Fakhar Z; Khan S; AlOmar SY; Alkhuriji A; Ahmad A
    Sci Rep; 2021 Jan; 11(1):234. PubMed ID: 33420186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity.
    Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2.
    Tripathi PK; Upadhyay S; Singh M; Raghavendhar S; Bhardwaj M; Sharma P; Patel AK
    Int J Biol Macromol; 2020 Dec; 164():2622-2631. PubMed ID: 32853604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.
    Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
    Verma AK; Aggarwal R
    Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking.
    Ribone SR; Paz SA; Abrams CF; Villarreal MA
    J Comput Aided Mol Des; 2022 Jan; 36(1):25-37. PubMed ID: 34825285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors.
    Jo S; Signorile L; Kim S; Kim MS; Huertas O; Insa R; Reig N; Shin DH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.